Genetic Testing

Developments in Multi-Gene Panel Tests for Breast Cancer

Developments in Multi-Gene Panel Tests for Breast Cancer

Numerous genetic mutations are linked to increased risk for breast cancer. Genetic testing can identify these mutations and guide patient management decisions. Over the past decade, multi-gene panel tests have gained traction in clinical settings. These evaluate up to 43 breast cancer-related genes, compared with limited BRCA 1 and BRCA2 (BRCA1/2) tests.

BRCA 1 and BRCA2 Genes: What Do Women Need to Know?

 BRCA 1 and BRCA2 Genes: What Do Women Need to Know?

Inherited genetic mutations can increase a woman’s risk of developing breast cancer. For instance, a mutation in two of the better-understood genes linked to a substantial increased risk of breast cancer, the BRCA1 and BRCA2 genes, account for up to:

SABCS 2014: Breast Cancer Prevention, Screening & Genetic Testing

SABCS 2014: Breast Cancer Prevention, Screening & Genetic Testing

This year at the San Antonio Breast Cancer Symposium (SABCS) there were two aspects of breast cancer that were clearly emphasized: use of ovarian suppression in premenopausal women with breast cancer and advances in genetic testing for hereditary cancer predisposition.

Results of the SOFT trial (further detailed by Dr. Wade Smith in this post), show a clear benefit to the addition of ovarian suppression in women under the age of 35. This benefit resembles that seen with the addition of Herceptin for HER2+ cancer, and now calls for a change in practice management.

Subscribe to RSS - Genetic Testing